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ABSTRACT
This study examined the antimicrobial resistance
of 1278 invasive Streptococcus pneumoniae isolates
from 41 Spanish laboratories participating in the
European Antimicrobial Resistance Surveillance
System (EARSS) during 2000 and 2001. Twenty-
nine laboratories participated during both years
and provided 950 of the isolates. Each laboratory
used its own susceptibility testing methods.
External quality assessment was performed annu-
ally by each participating laboratory. Significant
increases in penicillin and erythromycin resist-
ance were observed between 2000 and 2001. This
increase was particularly noticeable in isolates
from the laboratories participating during both
years and in isolates from children and elderly
patients.
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Antimicrobial resistance in Streptococcus pneumo-
niae is increasing in many parts of the world [1–3],
with the prevalence of penicillin-non-susceptible
isolates reaching 40–50% in some countries.
Macrolide resistance is also increasing, with an
estimated frequency of 28% worldwide, and
resistance rates exceeding those to b-lactams in
some countries [1,4]. Cross-resistance between
penicillins and macrolides has been reported
[1,5,6] and resistance to macrolides and penicillins
is particularly prevalent in Spain [2,6]. Inappro-
priate antibiotic consumption is one of the leading
causes of the emergence and spread of antibiotic
resistance in pneumococci [5,7–10].
The present study examined antimicrobial
resistance among invasive S. pneumoniae isolates
from 41 Spanish laboratories participating in the
European Antimicrobial Resistance Surveillance
System (EARSS) [11,12] during 2000 and 2001.
Twenty-nine laboratories participated during both
years. Different areas of the country were included,
covering an estimated 25% of the Spanish popu-
lation, with hospitals of various sizes and categor-
ies. Four of the 41 hospitals had > 1000 beds, 14 had
between 500 and 1000, 16 between 250 and 500, and
seven had < 250. Each laboratory identified
pneumococci using its own microbiological
techniques. The protocol for susceptibility testing
included penicillin, a third-generation cephalos-
porin (cefotaxime or ceftriaxone) and ciprofloxa-
cin. Other susceptibility data were also considered
when available. Susceptibilities were tested by
both disk-diffusion and Etests (AB Biodisk, Solna,
Sweden) in 26 laboratories, while the other
15 laboratories used commercial microdilution
systems. NCCLS breakpoints [13] were used to
analyse the results in all laboratories.
To assess the comparability of the susceptibility
results, an annual quality assurance exercise [14],
designed by the UK National External Quality
Assessment Scheme (UK NEQAS), was perfor-
med, which included strains with different resist-
ance phenotypes. The concordance (agreement
between reported and intended results) for detect-
ing penicillin and erythromycin resistance in
Spanish laboratories was at least 94% (2000) and
97% (2001) [12,14]. Data were collated at the
Centro Nacional de Microbiologı´a (Madrid,
Spain), where results were analysed and valid-
ated. Duplicate isolates were deleted, and dis-
crepancies and atypical results were resolved
by telephone. An annual report including all the
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data stored in the central database was sent to each
participating laboratory. EPI-Info for Windows,
v.6.04 (Centers for Disease Control, Atlanta, GA,
USA) was used for the statistical analyses.
The Spanish Ministry of Health and Consumer
Affairs maintains a drug database with a record of
all medicines acquired with National Health
System prescriptions [15,16]. This database was
used to gather information for the period 1995–
2001. The information was converted into defined
daily doses (DDDs) following WHO methodology
[17], and the number of DDD ⁄ 1000 inhabit-
ants ⁄day was calculated.
In total, 1278 invasive isolates of S. pneumoniae
(622 and 656 in 2000 and 2001, respectively) were
isolated in the 41 participating laboratories. Of
these, 75 were from cerebrospinal fluid (CSF) and
1203 from blood. The 29 laboratories participating
during both years provided 950 of the isolates
(472 and 478 in 2000 and 2001, respectively), of
which 54 were from CSF and 896 were from
blood.
Of the total 1278 isolates, 456 (35.7%) showed
decreased susceptibility to penicillin. Of the 1182
isolates for which MIC results were reported
(571 in 2000, 611 in 2001), 120 (10.2%) were
penicillin-resistant and 313 (26.5%) were penicil-
lin-intermediate. The number of penicillin-
non-susceptible isolates increased from 33.5%
(9.3% resistant, 24.2% intermediate; 95% CI,
29.7%-37.5%) in 2000 to 39.6% (11% resistant,
28.6% intermediate; 95% CI, 35.9%-43.6%) in
2001 (p 0.02; odds ratio 1.30; 95% CI, 1.02–1.67).
Erythromycin susceptibility was reported for
1246 isolates, of which 311 (25%) were resistant
and 19 (1.5%) were intermediate. The number of
erythromycin-resistant isolates in 2000 was 21.1%
(95% CI, 18.1%-24.5%) vs. 28.7% (95% CI, 25.4%-
32.4%) in 2001 (p 0.002; odds ratio 1.5; 95% CI,
1.15–1.97).
Susceptibility to clindamycin was reported for
830 isolates (431 and 399 strains in 2000 and 2001,
respectively). There were 23 erythromycin-resist-
ant and clindamycin-susceptible isolates in 2000,
representing 5.3% of all the isolates tested against
erythromycin and clindamycin, and 26.1% of
erythromycin-resistant isolates. In 2001, 31 isolates
had this phenotype, corresponding to 7.8% of the
isolates tested for erythromycin and clindamycin,
and 28.7% of erythromycin-resistant isolates.
The number of isolates with decreased suscep-
tibility to cefotaxime did not increase significantly
during this period (10.6% in 2000 vs. 11.7% in
2001).
Comparison of three patient age groups
showed that erythromycin resistance was more
frequent in 2001 than in 2000, with the highest
increases in the youngest and oldest age groups
(from 37.1% to 48.9% for the group aged
0–4 years; from 16.2% to 22.5% for the group
aged 5–64 years; and from 15.7% to 28.2% for the
group aged > 64 years).
Fluoroquinolone susceptibility was tested for
752 isolates (ciprofloxacin with 546 isolates and
levofloxacin with 206 isolates). Resistance to
ciprofloxacin, defined as an MIC of > 2 mg ⁄L,
and to levofloxacin was detected in eight strains
and one strain, respectively. No significant dif-
ference between fluoroqinolone resistance in 2000
and 2001 was observed.
For the laboratories which participated during
both years, isolates with decreased susceptibility
to penicillin increased from 35.2% (95% CI,
31.1%)39.7%) in 2000 to 42.1% (95% CI,
37.8%) 46.6%) in 2001 (p 0.036; odds ratio 1.34;
CI 95%, 1.01–1.77), while resistance to erythro-
mycin increased from 20.8% (95% CI, 17.4%)
24.7%) in 2000 to 30.1% (95% CI, 26.2%)34.5%)
in 2001 (p 0.0009; odds ratio 1.65; CI 95%, 1.21–
2.24) (Table 1). Among the pneumococcal isolates
with decreased penicillin susceptibility, 45%
(67 ⁄ 149) were also resistant to erythromycin in
2000 vs. 56.1% (105 ⁄ 187) in 2001 (p 0.04).
Antibiotic consumption in Spain from 1995 to
2001 is detailed in Table 2. Overall antibiotic use
decreased from 23.08 DDD ⁄ 1000 inhabitants ⁄day
in 1995 to 19.85 DDD ⁄ 1000 inhabitants ⁄day in
2001. The same trend was observed for the use of
penicillins and cephalosporins. The use of macro-
lides increased from 1995 to 1998, but use has
subsequently decreased slowly. While erythro-
mycin consumption underwent a steady decrease,
consumption of clarithromycin and azithromycin
increased steadily from 1995 to 2001. Over this
period, consumption of clarithromycin and
Table 1. Susceptibility to penicillin G and erythromycin
among invasive Streptococcus pneumoniae isolates from
laboratories participating during both 2000 and 2001
Antibiotic (year) n R (%) I (%) S (%)
Penicillin G (2000) 429 46 (10.7) 105 (24.5) 278 (64.8)
Penicillin G (2001) 454 44 (9.7) 147 (32.4) 263 (57.9)
Erythromycin (2000) 472 98 (20.8) 6 (1.3) 368 (77.9)
Erythromycin (2001) 478 144 (30.1) 6 (1.3) 328 (68.6)
R, resistant; I, intermediate; S, susceptible.
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azithromycin increased by factors of 1.72 and 3.62,
respectively.
Although increases in penicillin and erythro-
mycin resistance have been described previously
[18,19], the present study detected a 10% increase
in the prevalence of resistance to macrolides in
only 2 years. This increase appeared against a
high baseline level of antibiotic resistance and in
isolates from blood and CSF, in which antibiotic
resistance is usually lower than in respiratory
tract isolates [2,6]. Associated resistance to macro-
lides and penicillin was common, and 56% of the
erythromycin-resistant isolates were also penicil-
lin-non-susceptible in 2001, an 11% increase since
2000. A study in Finland reported an increase in
co-resistance from 32% in 1995 to 62% in 2000
among mainly respiratory tract isolates, but the
overall frequencies of resistance to macrolides
and penicillin remained relatively low (11% and
7%, respectively) [5].
Although total antibiotic consumption
decreased in Spain from 1995 to 2001, this was
not the case for some commonly used antimicro-
bial agents (Table 2). Other studies have des-
cribed a better association between macrolide
consumption and penicillin resistance than con-
sumption of penicillins [7,8]. Antibiotics are
recognised increasingly as the leading cause of
the spread of resistance in pneumococci [9], but
other factors, such as seasonal and geographical
variations in resistance rates and clonal turn-
over, may also contribute to the overall picture
[20].
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ABSTRACT
Turicella otitidis is a non-fermenting Gram-posit-
ive bacillus isolated almost exclusively from ear
exudates. Its significance in acute or chronic otitis
media is controversial. Over a 12-month period,
T. otitidis was isolated from nine ear exudates
from seven patients. Most of these were cases of
spontaneous drainage following recurrence of
otitis media after antimicrobial therapy that was
ineffective against T. otitidis. The MICs of penicil-
lin, levofloxacin, linezolid and vancomycin were
very low for all the isolates studied, but most
isolates displayed high resistance to macrolides
and lincosamides.
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Acute exudative otitis media is an inflammatory
process with the presence of fluid in the middle
ear, accompanied by fever and acute local pain.
Chronic otitis media is characterised by recurrent
episodes of variable duration, accompanied by
the production of exudate in the middle ear, and
may lead to perforation of the tympanic mem-
brane [1]. The fluid in the middle ear may persist
for considerable periods of time, and paediatric
patients with this pathology may have reduced
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